Skip to main content

Table 1 Summary of the studies for the IOP between HRT-treated patients and the control subjects

From: The association of estrogen-signaling pathways and susceptibility to open-angle glaucoma

AuthorCountryMean age (year)Duration of treatmentTypeIOP (mmHg)
HRTnon-HRT/pre
nMeanSDnMeanSD
Abramov et al. 2005 (a) [20]Israel66.4512 monthsNA (RO)10715.20.410715.50.4
Abramov et al. 2005 (b)NA (LO)10715.30.510715.20.2
Affinito et al. 2003 (a) [21]Italy53.73 monthsEstradiol + medroxyprogesterone acetate2414.122416.62.3
Affinito et al. 2003 (b)6 months2414.12.12416.62.4
Altintaş et al. 2004 (a) [22]Turkey46.12 monthsNA2012.331.762414.661.71
Altintaş et al. 2004 (b)2012.331.762016.162.32
Coksuer et al. 2011 [23]Turkey45–60*6 monthsEstradiol + drospirenone3413.42.73414.12.8
Guaschino et al. 2003 [24]Italy59.912 monthsEstradiol + dydrogesterone4014.83.24014.94.3
Özcan et al. 2017 (a) [25]Turkey49.96 monthsNA6113.93441.477615.411.76
Özcan et al. 2017 (b)6113.93441.477614.351.4
Sator et al. 1997 (a) [26]Austria55.71 weekEstradiol + medroxyprogesterone acetate (RO)2514.922515.22.6
Sator et al. 1997 (b)Estradiol + medroxyprogesterone acetate (LO)2515.22.42515.92.6
Sator et al. 1997 (c)1 monthEstradiol + medroxyprogesterone acetate (RO)2514.42.12515.22.6
Sator et al. 1997 (d)Estradiol + medroxyprogesterone acetate (LO)2514.22.32515.92,6
Sator et al. 1997 (e)3 monthsEstradiol + medroxyprogesterone acetate (RO)2513.81.92515.22.6
Sator et al. 1997 (f)Estradiol + medroxyprogesterone acetate (LO)2514.22.32515.92.6
Tint et al. 2010 (a) [27]Scotland59.35NAEstradiol only3311.812.9117213.252.85
Tint et al. 2010 (b)Combined5811.872.5117213.252.85
Toker et al. 2003 [28]Turkey52.41.5 monthsNA3013.292.283213.562.5
Vajaranant et al. 2016 (a) [29]USA71.8755 ± 1 yearsEstradiol (RO)80815.43.286015.83.3
Vajaranant et al. 2016 (b)Estradiol + progestin (RO)139715.63128215.73.1
Vajaranant et al. 2016 (c)Estradiol (LO)80815.33.186015.93.2
Vajaranant et al. 2016 (d)Estradiol + progestin (LO)139715.73128215.73
  1. n and SD represented the number of samples and standard deviation of IOP, respectively
  2. NA not available, RO right ocular, LO left ocular
  3. *Data presented as range